1-deamino 8-d-arginine Vasopressin (DDAVP) in Percutaneous Ultrasound-guided Renal Biopsy

Phase 4 Completed 162 enrolled University of Bari

RandomizedParallel-groupTriple-blindPrevention

Summary

The investigators evaluated the effect of pre-biopsy treatment with 1-deamino-8-D-arginine (DDAVP) on the incidence of post-biopsy bleeding complications. This is a IV phase single centre, double blind, randomized controlled study in patients, with acute and chronic nephropathy, undergoing ultrasound-guided percutaneous renal biopsy.

Timeline

Start: 2008-08
Primary completion: 2009-08
Completion: 2009-12

Outcome

Met primary endpoint

paper Desmopressin compared with placebo significantly decreased the risk of postbiopsy bleeding PMID 21354681 ↗

paper 11 of 80 [13.7%] vs 25 of 82 [30.5%]; relative risk, 0.45; 95% CI, 0.24-0.85; P = 0.01 PMID 21354681 ↗

Publications

Manno C, Bonifati C, Torres DD, Campobasso N, Schena FP. Desmopressin acetate in percutaneous ultrasound-guided kidney biopsy: a randomized controlled trial. Am J Kidney Dis. 2011 Jun;57(6):850-5. doi: 10.1053/j.ajkd.2010.12.019. Epub 2011 Feb 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Desmopressin	Peptide	0.3 ug/kg	Subcutaneous